Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) had its target price reduced by equities research analysts at Guggenheim from $23.00 to $18.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s price objective points to a potential upside of 98.24% from the company’s current price.
ZVRA has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Zevra Therapeutics in a report on Wednesday, August 19th. Cantor Fitzgerald dropped their target price on shares of Zevra Therapeutics from $25.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Zevra Therapeutics currently has an average rating of “Buy” and a consensus target price of $23.86.
Check Out Our Latest Analysis on ZVRA
Zevra Therapeutics Stock Performance
ZVRA opened at $9.08 on Monday. The business’s 50-day simple moving average is $10.99 and its 200 day simple moving average is $10.83. Zevra Therapeutics has a 52-week low of $8.01 and a 52-week high of $15.03. The firm has a market capitalization of $540.31 million, a PE ratio of 7.63 and a beta of 1.01.
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10. Zevra Therapeutics had a return on equity of 54.64% and a net margin of 52.80%. The firm had revenue of $37.76 million during the quarter, compared to the consensus estimate of $37.08 million. On average, research analysts forecast that Zevra Therapeutics will post 0.88 earnings per share for the current year.
Insider Activity
In related news, CEO Neil McFarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer owned 417,225 shares of the company’s stock, valued at approximately $4,693,781.25. The trade was a 4.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.70% of the company’s stock.
Institutional Investors Weigh In On Zevra Therapeutics
A number of institutional investors have recently made changes to their positions in ZVRA. EP Wealth Advisors LLC acquired a new stake in Zevra Therapeutics during the 3rd quarter worth approximately $117,000. Empowered Funds LLC bought a new position in Zevra Therapeutics during the 3rd quarter worth $820,000. Nantahala Capital Management LLC increased its position in Zevra Therapeutics by 9.2% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,963,096 shares of the company’s stock worth $21,535,000 after buying an additional 165,620 shares during the period. First Trust Advisors LP increased its position in Zevra Therapeutics by 16.9% during the 3rd quarter. First Trust Advisors LP now owns 12,266 shares of the company’s stock worth $135,000 after buying an additional 1,771 shares during the period. Finally, Royce & Associates LP lifted its holdings in shares of Zevra Therapeutics by 3.0% during the third quarter. Royce & Associates LP now owns 909,137 shares of the company’s stock worth $9,973,000 after buying an additional 26,479 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.
About Zevra Therapeutics
Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company’s products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.
See Also
- Five stocks we like better than Zevra Therapeutics
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
